LDS/Medical Tests/Progranulin (GRN) Gene Mutation Analysis

Progranulin (GRN) Gene Mutation Analysis

Progranulin is the precursor molecule of granulins, which are important glycosylated peptides that function in normal cellular development, tissue repair, and inflammation. The GRN gene, which is located in the long arm of chromosome 17 at position q21.31, codes for progranulin. Progranulin has a molecular weight of 88kDa and is cleaved into multiple biologically active forms collectively termed the granulins. The granulins are primarily active in microglial lysosomes where they aid in the proper functioning of the lysosomes and maintain the microglial response. Mutations in the GRN gene may lead to a deficiency of granulins and cause frontotemporal dementia (FTD) and ceroid lipofuscinosis 11 (CLN11).

More than 65 mutations in the GRN gene have been identified in patients with FTD. The familial form is transmitted as an autosomal dominant trait. Arg493Ter and R493* are the most common GRN mutations causing FTD. These mutations act as a stop signal in the progranulin synthesis and cause a massive build-up of TAR DNA-binding protein-43 (TDP-43) in the brain, which ultimately affects normal cerebral function. Patients with mutations develop FTD by their fifties or sixties and show symptoms of poor cognition, impaired movement and balance, and loss of intellect. On the other hand, CLN11 is not associated with TDP-43 accumulation, however, patients show similar symptoms along with seizures, cerebral ataxia, and decline in vision. 8 mutations in GRN are identified that cause CLN11.

  • Establishes the diagnosis of frontotemporal dementia
  • Aids in the differential diagnosis of dementia syndromes
  • Aids in the diagnosis of CLN11
  • Useful in screening individuals at risk

A positive result indicates the presence of mutation or pathogenic variants in the GRN gene.

A negative result indicates the absence of mutation or pathogenic variants in the GRN gene.

Negative for mutations analyzed (No mutations or pathogenic variants in the GRN gene were detected)

Polymerase Chain Reaction (PCR), gene deletion/ duplication analysis, next-generation sequencing (NGS), complete sequencing of GRN.

Whole blood (EDTA) or yellow-top (ACD) vial.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: unstable
MAPT, CHMP2B, TARDBP, VCP gene mutation analysis, neuronal biopsy, immunocytochemistry.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login